Understand the source comparison
Peptide Research News March 2026 Roundup: Clinical Trial Comparison
Survodutide Phase 3 NASH, Obesity 48% histological NASH resolution vs 12% placebo; 52% liver fat reduction 72 weeks p<0.001 for primary endpoint First dual-agonist to achieve fibrosis improvement in Phase 3. Regulatory filing expected Q2 2026 Mazdutide Phase 2
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- Phase 3
- NASH, Obesity
- 48% histological NASH resolution vs 12% placebo; 52% liver fat reduction
- 72 weeks
- p<0.001 for primary endpoint
- First dual-agonist to achieve fibrosis improvement in Phase 3. Regulatory filing expected Q2 2026
- Mazdutide
- Phase 2b
- Obesity, T2DM
- 12.6% mean body weight reduction; lower nausea rate than semaglutide (22% vs 38%)
- 48 weeks
- p=0.003 for weight loss
- Differentiated GI tolerability could position it as preferred dual-agonist for GI-sensitive patients
- P21
- Phase 2
- Traumatic Brain Injury
- 8.2% hippocampal volume preservation vs 3.1% atrophy; 4.8-point MOCA improvement
- 90 days
- p=0.009 for imaging endpoint
- First peptide to show structural neuroprotection with defined imaging biomarker
- Dihexa
- IND filed
- Alzheimer's Disease
- 42% increase in hippocampal synapse density (preclinical); IND approved March 2026
- Preclinical
- N/A (animal model)
- Oral bioavailability and synaptic repair mechanism distinguish it from existing AD therapies
- Thymalin
- Immune Senescence
- 26% increase in vaccine antibody response in adults 65+; 18% increase in naive T-cell counts
- 12 weeks
- p=0.021 for antibody response
- Thymic peptides now have reproducible immune biomarkers. No longer considered too diffuse to regulate
- Cerebrolysin
- Meta-analysis
- Stroke Recovery
- 3.2-point greater NIHSS improvement vs standard care (pooled data, n=1,823)
- 90 days post-stroke
- p=0.014
- Multi-peptide mixture complicates regulatory pathway but clinical effect is consistent across trials